Product NDC: | 53808-0246 |
Proprietary Name: | EPIVIR |
Non Proprietary Name: | lamivudine |
Active Ingredient(s): | 300 mg/1 & nbsp; lamivudine |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 53808-0246 |
Labeler Name: | State of Florida DOH Central Pharmacy |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA020564 |
Marketing Category: | NDA |
Start Marketing Date: | 20090701 |
Package NDC: | 53808-0246-1 |
Package Description: | 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0246-1) |
NDC Code | 53808-0246-1 |
Proprietary Name | EPIVIR |
Package Description | 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0246-1) |
Product NDC | 53808-0246 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | lamivudine |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 20090701 |
Marketing Category Name | NDA |
Labeler Name | State of Florida DOH Central Pharmacy |
Substance Name | LAMIVUDINE |
Strength Number | 300 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |